赛诺菲因涉嫌贬低流感疫苗而接受欧盟调查

2026-06-26 18:10

The European Commission has opened a formal antitrust investigation to assess whether Sanofi (SNY) has breached EU competition rules by carrying out a communication campaign that disparages the only rival flu vaccine recommended for vulnerable patients with risk factors.
One of the vaccines currently offered by Sanofi is an enhanced flu vaccine, which is specifically designed to provide greater protection against influenza for people over 60.
In the EU, this vaccine is marketed under the brand name 'Efluelda' and competes with another enhanced flu vaccine marketed by the company CSL Seqirus under the brand name 'Fluad.'
The commission is concerned that Sanofi (SNY) pursued a misleading communication campaign to disparage Fluad by portraying it as inferior to Efluelda, going against national vaccination recommendations in several member states.
The campaign primarily targeted healthcare professionals in Germany and France, the regulator's statement said.

More on Sanofi